Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sorting nexin 22 (SNX22) is a member of the sorting nexin protein family, characterized by the PX domain responsible for phosphatidylinositol 3-phosphate membrane binding. SNX22 localizes to the cytoplasm and is implicated in intracellular protein trafficking, participating in endosomal sorting and possibly in protein quality control. Two transcript variants exist: one protein-coding, one non-coding. Diseases associated with SNX22 include brittle bone disorder and osteogenesis imperfecta type IX, although it does not appear to be a known direct therapeutic target. Members of the sorting nexin family regulate diverse functions such as vesicular transport, autophagy, and protein homeostasis, with genetic defects impacting several disease pathways, but SNX22's specific disease associations and druggability have not been thoroughly characterized.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sorting nexin 22 (SNX22).